



# **Tuberculosis Country Profile 2021 Brunei Darussalam**

*Source: Global tuberculosis report 2021. Geneva: World Health Organization*

*Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.*

# Tuberculosis profile: Brunei Darussalam

Population 2020: 0.44 million

## Estimates of TB burden\*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	360 (310-420)	83 (71-95)
HIV-positive TB incidence	6 (1-13)	1.3 (0.34-2.9)
HIV-negative TB mortality	23 (19-26)	5.2 (4.4-6)
HIV-positive TB mortality	1 (0-1)	0.14 (0.08-0.21)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2020	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	7% (5-8)

## TB case notifications, 2020

Total new and relapse	314
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	100%
- % pulmonary	82%
- % bacteriologically confirmed <sup>^</sup>	96%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	37%
- % men (aged ≥15 years)	62%
Total cases notified	314

## TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	5	1.6%
- on antiretroviral therapy	5	100%

## Drug-resistant TB care\*\*, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases <sup>^</sup>	100%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases <sup>^</sup>	100%
Laboratory-confirmed cases - MDR/RR-TB <sup>^^</sup>	0
Patients started on treatment - MDR/RR-TB <sup>^^^</sup>	0
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB <sup>^^</sup>	0
Patients started on treatment - pre-XDR-TB or XDR-TB <sup>^^^</sup>	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	75%	253
Previously treated cases, excluding relapse, registered in 2019		0
HIV-positive TB cases registered in 2019	50%	2
MDR/RR-TB cases started on second-line treatment in 2018		0
XDR-TB cases started on second-line treatment in 2018		0


## TB preventive treatment, 2020

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100-100)


## TB financing

National TB budget, 2021 (US\$ millions)	
- Funding source, domestic	
- Funding source, international	
- unfunded	


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence




## HIV-negative TB mortality



## Incidence, Notified cases by age group and sex, 2020



## Cases attributable to five risk factors, 2020



## Total budget

(US\$ millions)	
-----------------	--

\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
 \*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
 ^ Calculated for pulmonary cases only  
 ^^ Includes cases with unknown previous TB treatment history  
 ^^ Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed